TY - JOUR
T1 - Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12)
AU - Mehta, L
AU - McNeill, M
AU - Hobart, J
AU - Wyrwich, K
AU - Poon, JL
AU - Auguste, P
AU - Zhong, J
AU - Elkins, J
PY - 2015/5
Y1 - 2015/5
N2 - Background: The 12-question Multiple Sclerosis (MS) Walking Scale (MSWS-12v1) is a
widely-used patient-reported outcome (PRO) measure of walking ability in MS.
Objective: To estimate the magnitude of an important change in MSWS-12v1 scores for the
interpretation of meaningful subject-level improvements across a 6-month trial of MS patients
with walking disability.
Methods: MOBILE was a 6-month exploratory study assessing fampridine’s effect on walking
ability in 132 people with MS. Three PRO measures assessed walking ability: MSWS-12v1,
EuroQol 5-Dimension-5 Level (EQ-5D-5L) mobility question, and a patient global impression of
change (PGIC) in overall walking ability. Pre-specified anchor- and distribution-based analyses
estimated the MSWS-12v1 change scores representing an important change for participants.
Results were triangulated to propose a single best value indicating meaningful improvement.
Results: Using Baseline to Week 2 through Week 24 change scores, anchor-based analyses
demonstrated mean and median improvements of 5.2-6.6 (PGIC) and 9.7-13.4 (EQ-5D-5L
mobility) points on the MSWS-12v1 indicated meaningful improvements. The distribution-based
estimate was 6.8 points. Triangulation across the results suggested an 8-point reduction in
MSWS-12v1 score represents an important subject-level change in these participants.
Conclusion: In similar MS clinical trials, an 8-point improvement on the MSWS-12v1is a
reasonable estimate of meaningful improvement in walking ability.
AB - Background: The 12-question Multiple Sclerosis (MS) Walking Scale (MSWS-12v1) is a
widely-used patient-reported outcome (PRO) measure of walking ability in MS.
Objective: To estimate the magnitude of an important change in MSWS-12v1 scores for the
interpretation of meaningful subject-level improvements across a 6-month trial of MS patients
with walking disability.
Methods: MOBILE was a 6-month exploratory study assessing fampridine’s effect on walking
ability in 132 people with MS. Three PRO measures assessed walking ability: MSWS-12v1,
EuroQol 5-Dimension-5 Level (EQ-5D-5L) mobility question, and a patient global impression of
change (PGIC) in overall walking ability. Pre-specified anchor- and distribution-based analyses
estimated the MSWS-12v1 change scores representing an important change for participants.
Results were triangulated to propose a single best value indicating meaningful improvement.
Results: Using Baseline to Week 2 through Week 24 change scores, anchor-based analyses
demonstrated mean and median improvements of 5.2-6.6 (PGIC) and 9.7-13.4 (EQ-5D-5L
mobility) points on the MSWS-12v1 indicated meaningful improvements. The distribution-based
estimate was 6.8 points. Triangulation across the results suggested an 8-point reduction in
MSWS-12v1 score represents an important subject-level change in these participants.
Conclusion: In similar MS clinical trials, an 8-point improvement on the MSWS-12v1is a
reasonable estimate of meaningful improvement in walking ability.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1413/viewcontent/Mehta_20MOBILE_20MCID_20Mult_20Scler_20J_20Exp_20Translation_20Clin_20Journal_20Revisions_20Draft2_20FAM_11953.pdf
M3 - Article
SN - 1352-4585
VL - 21
SP - 813
EP - 814
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 6
ER -